{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:55:59Z","timestamp":1775782559123,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012775","name":"Royal Melbourne Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-LABX-53\\u201301"],"award-info":[{"award-number":["ANR-10-LABX-53\\u201301"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejpb.2025.114817","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:18:49Z","timestamp":1753485529000},"page":"114817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exploring airway biological barriers: Implications for IgG-based therapeutics in respiratory infections"],"prefix":"10.1016","volume":"215","author":[{"given":"Gabrielle","family":"Pichon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Parent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6388-5146","authenticated-orcid":false,"given":"Stefanie","family":"Graeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-7809","authenticated-orcid":false,"given":"Anna","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-5424","authenticated-orcid":false,"given":"Thomas","family":"S\u00e9cher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Heuz\u00e9-Vourc\u2019h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2018","key":"10.1016\/j.ejpb.2025.114817_b0005","first-page":"1191","article-title":"Lower respiratory Infections Collaborators, estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Gbd","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejpb.2025.114817_b0010","article-title":"Global burden of lower respiratory infections during the last three decades","volume":"10","author":"Safiri","year":"2022","journal-title":"Front. Public Health"},{"issue":"2023","key":"10.1016\/j.ejpb.2025.114817_b0015","first-page":"166","article-title":"to 2019: an analysis for the Global Burden of Disease Study 2019","volume":"28","author":"Kang","year":"1990","journal-title":"Respirology"},{"key":"10.1016\/j.ejpb.2025.114817_b0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14715\/cmb\/2023.69.13.3","article-title":"Antiviral resistance in influenza viruses","volume":"69","author":"M\u00e1rquez Dom\u00ednguez","year":"2023","journal-title":"Cell. Mol. Biol. (Noisy-le-Grand)"},{"key":"10.1016\/j.ejpb.2025.114817_b0025","article-title":"Resistance (London), Grande-Bretagne, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations","author":"R. on A.","year":"2014","journal-title":"Review on Antimicrobial Resistance"},{"key":"10.1016\/j.ejpb.2025.114817_b0030","unstructured":"Antimicrobial Resistance Tackling the Burden in the European Union, OECD (2019). https:\/\/www.oecd.org\/en\/publications\/antimicrobial-resistance-tackling-the-burden-in-the-european-union_33cbfc1c-en.html (accessed December 12, 2024)."},{"key":"10.1016\/j.ejpb.2025.114817_b0035","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"HVTN 704\/HPTN 085 and HVTN 703\/HPTN 081 Study teams, two Randomized Trials of Neutralizing Antibodies to prevent HIV-1 Acquisition","author":"Corey","year":"2021","journal-title":"N Engl J Med 384"},{"key":"10.1016\/j.ejpb.2025.114817_b0040","first-page":"2293","article-title":"PALM Consortium Study Team, a Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","author":"S. Mulangu, L.E. Dodd, R.T. Davey, O. Tshiani Mbaya, M. Proschan, D. Mukadi, M. Lusakibanza Manzo, D. Nzolo, A. Tshomba Oloma, A. Ibanda, R. Ali, S. Coulibaly, A.C. Levine, R. Grais, J. Diaz, H.C. Lane, J.-J. Muyembe-Tamfum, PALM Writing Group, B. Sivahera, M. Camara, R. Kojan, R. Walker, B. Dighero-Kemp, H. Cao, P. Mukumbayi, P. Mbala-Kingebeni, S. Ahuka, S. Albert, T. Bonnett, I. Crozier, M. Duvenhage, C. Proffitt, M. Teitelbaum, T. Moench, J. Aboulhab, K. Barrett, K. Cahill, K. Cone, R. Eckes, L. Hensley, B. Herpin, E. Higgs, J. Ledgerwood, J. Pierson, M. Smolskis, Y. Sow, J. Tierney, S. Sivapalasingam, W. Holman, N. Gettinger, D. Vall\u00e9e, J. Nordwall","year":"2019","journal-title":"N Engl J Med 381"},{"key":"10.1016\/j.ejpb.2025.114817_b0045","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/AAC.00290-15","article-title":"Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies","volume":"59","author":"Leyva-Grado","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2025.114817_b0050","doi-asserted-by":"crossref","first-page":"e00052","DOI":"10.1128\/JVI.00052-20","article-title":"Airway delivery of Anti-influenza Monoclonal Antibodies results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies","volume":"94","author":"Vigil","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ejpb.2025.114817_b0055","article-title":"Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters","volume":"2","author":"Piepenbrink","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejpb.2025.114817_b0060","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2019.04.005","article-title":"In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration","author":"S\u00e9cher","year":"2019","journal-title":"J Control Release 303"},{"key":"10.1016\/j.ejpb.2025.114817_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12931-019-1057-3","article-title":"Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates","volume":"20","author":"Vonarburg","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejpb.2025.114817_b0070","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41385-019-0167-z","article-title":"Topical application of human-derived Ig isotypes for the control of acute respiratory infection evaluated in a human CD89-expressing mouse model","volume":"12","author":"Koernig","year":"2019","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(23)00393-6","article-title":"IBIO-INH-001 investigators, Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1\/2 trial","volume":"24","author":"Maranda","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejpb.2025.114817_b0080","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1152\/physrev.00040.2016","article-title":"Bacterial-Host Interactions: Physiology and Pathophysiology of respiratory Infection","volume":"98","author":"Hakansson","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejpb.2025.114817_b0085","series-title":"Molecular Medical Microbiology (second Edition)","first-page":"1499","article-title":"Chapter 84 - respiratory Tract Infections: a Clinical Approach","author":"Reed","year":"2015"},{"issue":"23","key":"10.1016\/j.ejpb.2025.114817_b0090","first-page":"00327","article-title":"The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies","volume":"S0939\u20136411","author":"Blin","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114817_b0095","article-title":"Impact of Biofilms on Chronic Infections and Medical challenges","volume":"15","author":"Mendhe","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejpb.2025.114817_b0100","doi-asserted-by":"crossref","unstructured":"Y. Al Ojaimi, T. Blin, J. Lamamy, M. Gracia, A. Pitiot, C. Denevault-Sabourin, N. Joubert, J.P. Pouget, V. Gouilleux-Gruart, N. Heuze-Vourc\u2019h, D. Lanznaster, S. Poty, T. Secher, Therapeutic antibodies - natural and pathological barriers and strategies to overcome them, Pharmacol Ther 233 (2022) 108022. doi: 10.1016\/j.pharmthera.2021.108022.","DOI":"10.1016\/j.pharmthera.2021.108022"},{"key":"10.1016\/j.ejpb.2025.114817_b0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1423-0410.2008.01143.x","article-title":"Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline","volume":"96","author":"Cramer","year":"2009","journal-title":"Vox Sang."},{"key":"10.1016\/j.ejpb.2025.114817_b0110","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0038-2024","article-title":"Infection and the microbiome in bronchiectasis","volume":"33","author":"Mac Aog\u00e1in","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejpb.2025.114817_b0115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2249.2002.01974.x","article-title":"Humoral immunity and bronchiectasis","volume":"130","author":"Stead","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2249.2006.03091.x","article-title":"Assessing immune function in adult bronchiectasis","volume":"144","author":"King","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5152\/TurkThoracJ.2020.19077","article-title":"Primary Immun Deficiency in patients with Non-Cystic Fibrosis Bronchiectasis and its Relationship with Clinical Parameters","volume":"22","author":"Bekir","year":"2021","journal-title":"Turk Thorac J"},{"key":"10.1016\/j.ejpb.2025.114817_b0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaip.2020.08.016","article-title":"Increased respiratory Viral Detection and Symptom Burden among patients with Primary Antibody Deficiency: results from the BIPAD Study","volume":"9","author":"Ponsford","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.ejpb.2025.114817_b0135","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jaci.2021.12.778","article-title":"Airway inflammation and dysbiosis in antibody deficiency despite the presence of IgG","volume":"149","author":"Schnell","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1183\/20734735.042912","article-title":"Induced sputum analysis: step by step","volume":"9","author":"Weiszhar","year":"2013","journal-title":"Breathe"},{"key":"10.1016\/j.ejpb.2025.114817_b0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1099\/jmm.0.45969-0","article-title":"Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung","volume":"54","author":"Sriramulu","year":"2005","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejpb.2025.114817_b0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/978-1-4939-0473-0_49","article-title":"Methods for studying biofilm dispersal in Pseudomonas aeruginosa","volume":"1149","author":"Barraud","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejpb.2025.114817_b0155","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/jac\/dkab068","article-title":"A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms","volume":"76","author":"Frisch","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2025.114817_b0160","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nrmicro.2017.99","article-title":"Targeting microbial biofilms: current and prospective therapeutic strategies","volume":"15","author":"Koo","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejpb.2025.114817_b0165","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","article-title":"Physiology and pathophysiology of human airway mucus","volume":"102","author":"Hill","year":"2022","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejpb.2025.114817_b0170","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2025.114817_b0175","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/nn800508f","article-title":"A nanoengineering approach for investigation and regulation of protein immobilization","volume":"2","author":"Tan","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2025.114817_b0180","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1939605","article-title":"The biophysical principles underpinning muco-trapping functions of antibodies","volume":"18","author":"Schaefer","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ejpb.2025.114817_b0185","article-title":"Diffusion of Immunoglobulin G in Shed Vaginal Epithelial Cells and in Cell-Free Regions of Human Cervicovaginal Mucus","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114817_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076176","article-title":"Differential Binding of IgG and IgA to Mucus of the Female Reproductive Tract","volume":"8","author":"Fahrbach","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2025.114817_b0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1107\/S205225251402209X","article-title":"In-depth analysis of subclass-specific conformational preferences of IgG antibodies","volume":"2","author":"Tian","year":"2015","journal-title":"IUCrJ"},{"key":"10.1016\/j.ejpb.2025.114817_b0200","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.4049\/jimmunol.159.7.3372","article-title":"Flexibility of human IgG subclasses","volume":"159","author":"Roux","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0205","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1038\/s41467-023-39699-5","article-title":"Glycopeptide database search and de novo sequencing with PEAKS GlycanFinder enable highly sensitive glycoproteomics","volume":"14","author":"Sun","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2025.114817_b0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imr.13407","article-title":"The importance of IgG glycosylation-what did we learn after analyzing over 100,000 individuals","volume":"328","author":"Kri\u0161ti\u0107","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejpb.2025.114817_b0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.ejpb.2025.114817_b0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/elps.201600425","article-title":"Assessment of disulfide and hinge modifications in monoclonal antibodies","volume":"38","author":"Moritz","year":"2017","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ejpb.2025.114817_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010525","article-title":"Oxidation increases mucin polymer cross-links to stiffen airway mucus gels","author":"Yuan","year":"2015","journal-title":"Sci Transl Med 7"},{"key":"10.1016\/j.ejpb.2025.114817_b0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1006\/bbrc.1998.8633","article-title":"Enzymatic activation of immunoglobulin binding factor in female reproductive tract","volume":"246","author":"Mori","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejpb.2025.114817_b0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/gut.51.2.169","article-title":"Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids","volume":"51","author":"Kobayashi","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.ejpb.2025.114817_b0240","first-page":"271","article-title":"Primary Immunodeficiency Disorders in children with Non-Cystic Fibrosis Bronchiectasis, Eur Ann Allergy","volume":"52","author":"\u00c7a\u011fda\u015f","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0245","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis","volume":"201","author":"Ramsey","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2025.114817_b0250","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fny026","article-title":"Diversification of Pseudomonas aeruginosa within the cystic fibrosis lung and its effects on antibiotic resistance","volume":"365","author":"Clark","year":"2018","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.ejpb.2025.114817_b0255","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1016\/S0142-9612(02)00202-8","article-title":"Polyclonal human antibodies reduce bacterial attachment to soft contact lens and corneal cell surfaces","volume":"23","author":"Rediske","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2025.114817_b0260","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1097-4636(200008)51:2<224::AID-JBM11>3.0.CO;2-G","article-title":"Pooled human immunoglobulins reduce adhesion of Pseudomonas aeruginosa in a parallel plate flow chamber","volume":"51","author":"Poelstra","year":"2000","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ejpb.2025.114817_b0265","first-page":"93","article-title":"Inhibition of biofilm formation by monoclonal antibodies against Staphylococcus epidermidis RP62A accumulation-associated protein","volume":"12","author":"Sun","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.ejpb.2025.114817_b0270","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109940118","article-title":"Architecture of cell-cell junctions in situ reveals a mechanism for bacterial biofilm inhibition","volume":"118","author":"Melia","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejpb.2025.114817_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102867","article-title":"Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections","volume":"59","author":"Novotny","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejpb.2025.114817_b0280","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02392-2018","article-title":"The significant global economic burden of bronchiectasis: a pending matter","volume":"53","author":"Guan","year":"2019","journal-title":"Eur. Respir. J."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:16:53Z","timestamp":1756912613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":56,"alternative-id":["S0939641125001948"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114817","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring airway biological barriers: Implications for IgG-based therapeutics in respiratory infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114817"}}